Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounjaro® (tirzepatide), the innovative obesity and diabetes medicine developed by Eli Lilly and Company, will be ...

Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.

BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounja ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended alongside a controlled diet and regular physical activity.

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

30 individual IBT sessions with a registered dietitian The dose escalation regimen was consistent in all trials. Subcutaneous semaglutide was initiated in all participants at a dose of 0.25 mg ...

With political action underway through an executive order from President Donald Trump and pharmaceutical industry shifts emerging, the question remains whether these changes will lead to sustained ...